Prevention and treatment

The most straightforward approach to managing mitochondrial toxicity and its associated conditions is discontinuing mitotoxic drugs. Switching from d4T (stavudine, Zerit) or ddI (didanosine, Videx/VidexEC) to other nucleoside reverse transcriptase inhibitors (NRTIs), especially abacavir (Ziagen) or tenofovir (Viread) leads to improvements in lipoatrophy, peripheral neuropathy, pancreatitis, and other side-effects. Most patients can safely restart alternative NRTIs after lactic acidosis resolves or other symptoms improve.1 2 It is unclear whether some degree of mitochondrial toxicity is irreversible.

Although damage to the mitochondria improves slowly after the offending drugs are stopped, symptoms can improve quickly.3 Elevated lactate levels typically resolve fairly soon after stopping the offending drug and mitochondrial DNA levels gradually increase.3 Some conditions such as peripheral neuropathy resolve relatively quickly. Lipoatrophy, which typically takes a long time to develop, also resolves very slowly, if at all.4 5 6

Some experts have proposed ‘NRTI-sparing’ regimens that contain only non-nucleoside reverse transcriptase inhibitors and protease inhibitors, but this approach remains experimental. 'Drug holidays' and strategic treatment interruptions are also unproven approaches to preventing or managing side-effects.

Experimental therapies

Certain nutrients are known to be necessary for proper mitochondrial function and cellular metabolism. The release of damaging free radicals is increased during anaerobic energy production when mitochondria are impaired. This suggests that supplementation of certain nutrients and antioxidants may prove beneficial in managing mitochondrial toxicity.

Several nutritional therapies have been used in an attempt to prevent or treat mitochondrial damage.7 There are anecdotal reports and small studies that suggest combinations of thiamine (vitamin B1), riboflavin (B2), vitamins C and E, carnitine, and co-enzyme Q10 may stabilise lactate levels and reduce the risk of death in patients with lactic acidosis.8 1 Dietary supplements such as selenium, N-acetyl-cysteine (NAC), and alpha-lipoic acid appear to raise levels of glutathione, a major intracellular antioxidant.

Acetyl-L-carnitine, which promotes mitochondrial energy production, reversed the loss of nerve fibres in the skin and reduced neuropathic pain in one small study.9 Researchers in London reported that dicholoroacetate appeared to help resolve symptoms in three out of four patients with NRTI-induced acidosis.10 Finally, German researchers have reported that the supplement mitocnol (NucleomaxX), which is derived from sugar cane and contains uridine, appears to reverse side-effects attributed to NRTI-induced mitochondrial toxicity.11 12

References

  1. Falco V et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 34: 838-846, 2002
  2. Lonergan JT et al. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS 17: 2495-2499, 2003
  3. Mussini C et al. Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. AIDS 19: 1627-1633, 2005
  4. Carr A et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288: 207-215, 2002
  5. Martin A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18: 1029-1036, 2004
  6. Moyle G et al. A 48 week, randomized, open label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 33: 22-28, 2003
  7. Schambelan M et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 31: 257-275, 2002
  8. Gerard Y et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 14: 2723-2730, 2000
  9. Hart AM et al. Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 18: 1549-1560, 2004
  10. Davies E et al. Reduction in hyperlactatemia with dichloroacetate in HIV-1 infected patients. Eighth European Conference on Clinical Aspects of HIV Infection and Treatment, Athens, abstract P147, 2001
  11. Walker UA et al. Beneficial effects of oral uridine in mitochondrial toxicity. AIDS 18: 1085-1086, 2004
  12. Banasch M et al. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients. AIDS 20: 1554-1556, 2006
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.